This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Upgraded, Undervalued Stocks

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Myriad Genetics

The molecular diagnostic company reported last month second-quarter earnings of $28.3 million, or 33 cents a share. Earnings increased 17% from the previous year.

Myriad Genetics' estimated P/E for next year is 16.7. The average forward P/E among biotechnology companies is 44.38. United Therapeutics (UTHR) had a forward P/E of 7.81.

Of Myriad Genetics' Prolaris presentation at the ASCO-GU conference Thursday, Oppenheimer analysts wrote in a report Thursday, "MYGN is ramping up its sales force, doubling the size to 20, as mgmt believes prostate cancer to represent a large opportunity with an annual incidence of 241k pre-prostatectomy patients and a prevalence of 1M post-prostatectomy patients. Initial launch is planned in the pre-prostatectomy indication, with payor talks ongoing."

Eleven of the 20 analysts who cover the company rated it a buy. Nine considered it a hold.

TheStreet Ratings gives Myriad a B- grade with a $27.69 price target. The stock closed Thursday at $23.66 and has increased 15% year to date.

>>To see these stocks in action, visit the 4 Upgraded, Undervalued Stocks portfolio on Stockpickr.

The following companies also received upgrades to buy from TheStreet Ratings Friday.
  • Hyatt Hotels:(H) B- grade from TheStreet Ratings and a $49.61 price target. The stock closed Thursday at $42.84.
  • Intersil:(ISIL) B grade from TheStreet Ratings and a $13.48 price target. The stock closed Thursday at $11.02.

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to:

>To follow the writer on Twitter, go to Alexandra Zendrian.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAWW $48.66 26.98%
CDNS $23.06 -0.35%
EXXI $0.08 -10.27%
MYGN $34.19 0.74%
AAPL $93.24 -0.41%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs